This morning we watched Apellis Pharmaceuticals rise 2.0% to a price of $61.05 per share. The mid-cap Pharmaceutical company is now trading -17.22% below its average target price of $73.75. Analysts have set target prices ranging from $44.0 to $95.0 per share for Apellis Pharmaceuticals, and have given the stock an average rating of buy.
Apellis Pharmaceuticals has an elevated short interest of 15.0%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 8.32. Since 13.47% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. 97.5% of Apellis Pharmaceuticals shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Apellis Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Wellington Management Group, LLP | 13% | 15,167,044 | $925,948,024 |
| 2023-09-30 | Avoro Capital Advisors LLC | 9% | 11,111,111 | $678,333,318 |
| 2023-09-30 | EcoR1 Capital, LLC | 9% | 10,899,859 | $665,436,383 |
| 2023-09-30 | Vanguard Group Inc | 8% | 9,469,977 | $578,142,088 |
| 2023-09-30 | T. Rowe Price Investment Management, Inc. | 6% | 6,519,471 | $398,013,699 |
| 2023-09-30 | Blackrock Inc. | 4% | 5,272,746 | $321,901,139 |
| 2023-09-30 | Jennison Associates LLC | 3% | 3,542,209 | $216,251,856 |
| 2023-09-30 | State Street Corporation | 3% | 3,238,114 | $197,686,857 |
| 2023-09-30 | Octagon Capital Advisors LP | 3% | 3,130,000 | $191,086,497 |
| 2023-09-30 | FMR, LLC | 2% | 2,259,766 | $137,958,712 |
For these reasons, we consider that the Apellis Pharmaceuticals is the subject of mixed market sentiment.
